Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Padmanee Sharma

Showing results (141-150 of 216) with videos related to

Pageof 22
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2016
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T CellsChad Tang, James W Welsh, Patricia de Groot, et al.
The Lancet. Haematology|August 12, 2019
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 studyFarhad Ravandi, Rita Assi, Naval Daver, et al.
Cancer Immunology Research|January 18, 2018
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 BlockadeCharlotte E Ariyan, Mary Sue Brady, Robert H Siegelbaum, et al.
Cancer Research|November 9, 2016
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by RadiotherapyXiaohong Wang, Jonathan E Schoenhals, Ailin Li, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, et al.
Investigational New Drugs|November 22, 2017
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experienceTakeo Fujii, Rivka R Colen, Mehmet Asim Bilen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Characterization and Comparison of GITR Expression in Solid TumorsLuis Vence, Samantha L Bucktrout, Irina Fernandez Curbelo, et al.
Cancer|March 4, 2020
Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitorsBetül Oran, Guillermo Garcia-Manero, Rima M Saliba, et al.
Cancer Cell|May 27, 2014
Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survivalBerna C Özdemir, Tsvetelina Pentcheva-Hoang, Julienne L Carstens, et al.
Oncology|October 20, 2024
Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular CarcinomaMichael LaPelusa, Shadi Chamseddine, Hop Sanderson Tran Cao, et al.
Pageof 22

Showing results (141-150 of 216) with videos related to

Sort By:
Pageof 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2016
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T CellsChad Tang, James W Welsh, Patricia de Groot, et al.
The Lancet. Haematology|August 12, 2019
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 studyFarhad Ravandi, Rita Assi, Naval Daver, et al.
Cancer Immunology Research|January 18, 2018
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 BlockadeCharlotte E Ariyan, Mary Sue Brady, Robert H Siegelbaum, et al.
Cancer Research|November 9, 2016
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by RadiotherapyXiaohong Wang, Jonathan E Schoenhals, Ailin Li, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, et al.
Investigational New Drugs|November 22, 2017
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experienceTakeo Fujii, Rivka R Colen, Mehmet Asim Bilen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Characterization and Comparison of GITR Expression in Solid TumorsLuis Vence, Samantha L Bucktrout, Irina Fernandez Curbelo, et al.
Cancer|March 4, 2020
Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitorsBetül Oran, Guillermo Garcia-Manero, Rima M Saliba, et al.
Cancer Cell|May 27, 2014
Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survivalBerna C Özdemir, Tsvetelina Pentcheva-Hoang, Julienne L Carstens, et al.
Oncology|October 20, 2024
Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular CarcinomaMichael LaPelusa, Shadi Chamseddine, Hop Sanderson Tran Cao, et al.
Pageof 22